title: The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus.
abstract: Glucocorticoids are widely used in the treatment of lupus patients, and adverse effects, which include osteoporosis and associated fractures, are frequent. Treatment of osteoporosis of young patients should be effective and not harmful to bone growth and remodeling. Bisphosphonates are drugs that decrease the incidence of bone fractures, but their use in juvenile patients is still controversial because of their possible side effects on the growing skeleton. However, recently published studies showed that linear growth continued normally after treatment with these drugs, and there was no excessive suppression of bone remodeling or mineralization defects. Zoledronic acid is a new intravenous bisphosphonate that has been approved by the US FDA for use with hypercalcemia of malignancies and might be an effective treatment for postmenopausal osteoporosis. The authors report a case of a young girl with systemic lupus who developed multiple vertebral collapses due to glucocorticoid therapy, and zoledronic acid was used producing significant clinical and densitometric improvement.
authors.affiliation: Division of Rheumatology and Nephrology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
authors.forename: Sonia Cristina de Magalhães
authors.initials: SC
authors.lastname: Souza
authors.forename: Claudia Tereza Lobato
authors.initials: CT
authors.lastname: Borges
authors.forename: Vanda
authors.initials: V
authors.lastname: Jorgetti
authors.forename: Rosa Maria Rodrigues
authors.initials: RM
authors.lastname: Pereira
mesh_terms: D000293:Adolescent; D001379:Azathioprine / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002574:Cervical Vertebrae / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects; D016103:Spinal Fractures / Q000139:chemically induced*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D001379:Azathioprine; D011241:Prednisone